Advertisement

Anonymous sources say that Baxter is nearing an agreement with European Commission anti-trust regulators over the $4 billion acquisition of Swedish dialysis giant Gambro AB.

Baxter proposes fixes to EU’s antitrust concerns

Healthcare giant Baxter (NYSE:BAX) may be on the verge of closing its $4 billion buyout of Swedish dialysis devices maker Gambro AB after offering to divest some of its assets in order to appease European regulators, according to anonymous sources cited by Reuters.

"People familiar with the matter" told the news wire that negotiations with EU regulators are moving forward and that Baxter offered to sell off its global continuous renal replacement therapy business in order to stem anti-trust concerns.

Advertisement
Advertisement